

**Advanced Molecules Ltd**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 30 June 2025**

**Advanced Molecules Ltd**  
**CONTENTS**

	<b>Page</b>
Directors' Responsibilities Statement	3
Statement of Financial Position	4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 8

# **Advanced Molecules Ltd**

## **DIRECTORS' RESPONSIBILITIES STATEMENT**

for the financial year ended 30 June 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### **Signed on behalf of the board**

---

**James Norton**  
Director

**12 February 2026**

---

**Eoin Long**  
Director

**12 February 2026**

**Advanced Molecules Ltd**  
**STATEMENT OF FINANCIAL POSITION**

as at 30 June 2025

	Notes	2025 €	2024 €
<b>Non-Current Assets</b>			
Intangible assets	4	668,436	519,162
<b>Current Assets</b>			
Debtors	5	4,753	8,139
Cash and cash equivalents		569,606	4,327
		574,359	12,466
<b>Creditors: amounts falling due within one year</b>	6	(11,058)	(75,723)
<b>Net Current Assets/(Liabilities)</b>		563,301	(63,257)
<b>Total Assets less Current Liabilities</b>		1,231,737	455,905
<b>Creditors:</b>			
amounts falling due after more than one year	7	(962,500)	-
<b>Net Assets</b>		269,237	455,905
<b>Capital and Reserves</b>			
Called up share capital presented as equity		8	8
Share premium account	8	499,999	499,999
Retained earnings		(230,770)	(44,102)
<b>Shareholders' Funds</b>		269,237	455,905

We as Directors of Advanced Molecules Ltd, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

**Approved by the board on 12 February 2026 and signed on its behalf by:**

\_\_\_\_\_  
**James Norton**  
**Director**

\_\_\_\_\_  
**Eoin Long**  
**Director**

**Advanced Molecules Ltd**  
**STATEMENT OF CHANGES IN EQUITY**

as at 30 June 2025

	<b>Called up share capital €</b>	<b>Share premium account €</b>	<b>Retained earnings €</b>	<b>Total €</b>
<b>At 1 July 2023</b>	-	499,999	-	499,999
Loss for the financial year	-	-	(44,102)	(44,102)
Net proceeds of equity Ordinary share issue	8	-	-	8
<b>At 30 June 2024</b>	<b>8</b>	<b>499,999</b>	<b>(44,102)</b>	<b>455,905</b>
Loss for the financial year	-	-	(186,668)	(186,668)
<b>At 30 June 2025</b>	<b>8</b>	<b>499,999</b>	<b>(230,770)</b>	<b>269,237</b>

# Advanced Molecules Ltd

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

### 1. General Information

Advanced Molecules Ltd is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 739954. The registered office of the company is Research and Experimental Development on Biotechnology The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the financial year ended 30 June 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

#### Intangible assets

Intangible assets are valued at cost less accumulated amortisation.

#### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

#### Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

#### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

#### Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Statement of Financial Position date.

# Advanced Molecules Ltd

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

### Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Statement of Financial Position date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income Statement.

### Research and development

Development expenditure is written off in the same financial year unless the directors are satisfied as to the technical, commercial and financial viability of individual projects. In this situation, the expenditure is deferred and amortised over the period from which the company is expected to benefit.

### Ordinary share capital

The ordinary share capital of the company is presented as equity.

### 3. Employees

There were no employees during this period.

### 4. Intangible assets

	Development Costs €	Total €
<b>Cost</b>		
At 1 July 2024	519,162	519,162
Additions	149,274	149,274
	<u>668,436</u>	<u>668,436</u>
At 30 June 2025	668,436	668,436
	<u>668,436</u>	<u>668,436</u>
<b>Net book value</b>		
At 30 June 2025	<u>668,436</u>	<u>668,436</u>
At 30 June 2024	<u>519,162</u>	<u>519,162</u>

### 5. Debtors

	2025 €	2024 €
Other debtors	7	7
Taxation	4,746	8,132
	<u>4,753</u>	<u>8,139</u>

### 6. Creditors Amounts falling due within one year

	2025 €	2024 €
Trade creditors	7,558	-
Other creditors	-	50,000
Accruals	3,500	25,723
	<u>11,058</u>	<u>75,723</u>

### 7. Creditors Amounts falling due after more than one year

	2025 €	2024 €
Other loans	962,500	-

**Advanced Molecules Ltd**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 30 June 2025

**8. Reserves**

	<b>Share premium account</b>	<b>Income statement</b>	<b>Total</b>
	€	€	€
At 1 July 2024	499,999	(44,102)	455,897
Loss for the financial year	-	(186,668)	(186,668)
At 30 June 2025	<u><u>499,999</u></u>	<u><u>(230,770)</u></u>	<u><u>269,229</u></u>

**Share Premium Reserve**

The amount carried forward is the premium that arose from the issue of shares in 2023.

**9. Capital commitments**

The company had no material capital commitments at the financial year-ended 30 June 2025.

**10. Events After the End of the Reporting Period**

There have been no significant events affecting the company since the financial year-end.

**11. Approval of financial statements**

The financial statements were approved and authorised for issue by the board of directors on 12 February 2026.